Tenon Medical (NASDAQ:TNON) Given New $8.00 Price Target at Maxim Group

Tenon Medical (NASDAQ:TNON) had its price objective reduced by Maxim Group from $22.00 to $8.00 in a report published on Friday,Benzinga reports. They currently have a buy rating on the stock.

Separately, Benchmark reissued a “speculative buy” rating and set a $3.00 price target on shares of Tenon Medical in a report on Wednesday, August 14th.

Tenon Medical Trading Down 3.6 %

TNON stock traded down $0.10 during midday trading on Friday, hitting $2.71. The stock had a trading volume of 145,150 shares, compared to its average volume of 752,918. The stock has a 50-day simple moving average of $4.05 and a 200 day simple moving average of $1.86. Tenon Medical has a 52 week low of $2.61 and a 52 week high of $22.32. The firm has a market capitalization of $1.38 million, a price-to-earnings ratio of -0.10 and a beta of 2.15.

Tenon Medical (NASDAQ:TNON) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($1.02) EPS for the quarter. The firm had revenue of $0.90 million during the quarter. Tenon Medical had a negative net margin of 413.88% and a negative return on equity of 4,819.46%.

About Tenon Medical

Tenon Medical, Inc, a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints.